Table 4.
Patient demographic and clinical characteristics at baseline
| Variables | Patients (n = 5109) |
|---|---|
| Male (patients) | 52.4% |
| Age (y) | 68.7 ± 11.4 |
| Age ≥80 y (patients) | 17.4% |
| Body mass index (kg/m2) | 24.7 ± 4.0 |
| Current smoker (patients) | 9.1% |
| History of cardiovascular diseasea (patients) | 23.6% |
| Complications (patients) | |
| Diabetes, glucose tolerance disorder | 32.4% |
| Dyslipidemia | 57.1% |
| High‐normal normotension or grade I‐III hypertension | 83.5% |
| Renal disease (eGFR ≥60 mL/min/1.73 m2 or positive proteinuria) | 19.9% |
| Atrial fibrillation | 9.3% |
| Metabolic syndrome | 10.5% |
| Chronic obstructive pulmonary disease | 1.8% |
| Sleep apnea syndrome | 4.8% |
| Main concomitant drugs (patients) | |
| Antihypertensives | 83.4% |
| Statins | 46.8% |
| Aspirin | 16.1% |
| Clinic blood pressure, mm Hg | |
| Systolic | 133.5 ± 16.6 |
| Diastolic | 76.8 ± 10.6 |
| Cardio‐ankle vascular index | 8.8 ± 1.4 |
| Ankle‐branchial index | 1.1 ± 0.1 |
Values are presented as mean ± SD, or percentage of patients.
Abbreviation: eGFR, estimated glomerular filtration rate.
a
Stroke, percutaneous coronary revascularization or myocardial infarction.